NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/12/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1.88 mln
Float2.51 mln
Earnings Date08/14/2026
Piotroski F-Score
4
/ 9
Borderline
Relative Strength
7
/ 100
Severely lagging
Debt / Equity
1.54
High leverage
Pre-Tax Margin
17,180%
Exceptional margin
ROE
-169
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Valion Bio Inc. is a late-stage pharmaceutical company based in San Antonio, Texas, focused on developing treatments for radiation-related injuries and immune system disorders. Its main drug, Entolimod, is being tested for acute radiation syndrome, low white blood cell counts, and immune exhaustion, while a related compound called Entolasta targets long-term conditions linked to aging immune systems. The company also provides contract manufacturing services to other life sciences businesses. Originally founded in 2016 under the name Tivic Health Systems Inc., it adopted its current name in April 2026.
